Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells by Turner, John J. et al.
Cell-penetratingpeptideconjugatesofpeptidenucleic
acids (PNA) as inhibitors of HIV-1 Tat-dependent
trans-activation in cells
John J. Turner, Gabriela D. Ivanova, Birgit Verbeure, Donna Williams,
Andrey A. Arzumanov, Saı ¨d Abes
1, Bernard Lebleu
1 and Michael J. Gait*
Laboratory of Molecular Biology, Medical Research Council, Hills Road, Cambridge CB2 2QH, UK and
1UMR 5124 CNRS, CC 086, Universite ´ Montpellier 2, Place Euge `ne Bataillon, 34095 Montpellier, France
Received October 6, 2005; Revised and Accepted November 14, 2005
ABSTRACT
The trans-activation response (TAR) RNA stem–loop
that occurs at the 50 end of HIV RNA transcripts is
an important antiviral target and is the site of inter-
action of the HIV-1 Tat protein together with host cel-
lular factors. Oligonucleotides and their analogues
targeted to TAR are potential antiviral candidates.
We have investigated a range of cell penetrating
peptide (CPP) conjugates of a 16mer peptide nucleic
acid (PNA) analogue targeted to the apical stem–loop
ofTARandshowthatdisulfide-linkedPNAconjugates
of two types of CPP (Transportan or a novel chimeric
peptide R6-Penetratin) exhibit dose-dependent
inhibition of Tat-dependent trans-activation in a
HeLa cell assay when incubated for 24 h. Activity is
reached within 6 h if the lysosomotropic reagent
chloroquine is co-administered. Fluorescein-labelled
stably-linked conjugates of Tat, Transportan or
Transportan TP10 with PNA were inactive when
delivered alone, but attained trans-activation inhibi-
tion in the presence of chloroquine. Confocal micro-
scopy showed that such fluorescently labelled
CPP–PNA conjugates were sequestered in endo-
somal or membrane-bound compartments of HeLa
cells, which varied in appearance depending on the
CPP type. Co-administration of chloroquine was
seen in some cases to release fluorescence from
such compartments into the nucleus, but with differ-
ent patterns depending on the CPP. The results show
that CPP–PNA conjugates of different types can
inhibit Tat-dependent trans-activation in HeLa cells
and have potential for development as antiviral
agents. Endosomal or membrane release is a major
factor limiting nuclear delivery and trans-activation
inhibition.
INTRODUCTION
Efﬁcient delivery of oligonucleotides and their analogues
through cell membranes to allow interaction with intracellular
RNA targets and to control gene expression has proved to be a
signiﬁcant challenge. Oligonucleotide analogues that carry
negative charges (e.g. phosphodiesters or phosphorothioates)
are often delivered into common laboratory cell lines in cul-
ture (such as HeLa cells) by complexation with cationic lipids
(1), of which there is now a wide choice. However, there are
usually limiting lipid-associated cell toxicities and stability
disadvantages for therapeutic use. Charge-neutral peptide nuc-
leic acids (PNAs) (2) and phosphorodiamidate morpholino
oligomers (PMO) (3) have been developed as oligonucleotide
analogues that are unaffected by cellular nucleases and which
have strong RNA binding. It was hoped that the lack of neg-
ative charge might facilitate cell uptake, but cell membrane
translocation of unmodiﬁed PNA and PMO has proved to be
as inefﬁcient as for phosphate-containing oligonucleotides and
analogues (4).
Recently, certain peptides [known as cell penetrating
peptides (CPPs) or protein transduction domains] have been
identiﬁed that have strong cell translocation properties and
potential for drug delivery (5). A number of promising cell
delivery studies have focussed on covalent conjugates of CPPs
with various types of cargo [reviewed in Refs (6–8)] including
oligonucleotides and their analogues [reviewed in Refs (9–
11)]. Whereas conjugates of CPPs with negatively charged
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doi:10.1093/nar/gki991phosphodiester or phosphorothioate oligonucleotides have had
mixed results in recent cell delivery studies (12–15), several
reports have showed enhanced cellular delivery and biological
activity of PNA covalently attached to CPPs [reviewed in
Refs (9,11)].
In common with many other steric block oligonucleotide
analogue types, PNA does not induce RNase H-dependent
RNA cleavage when bound to an RNA target. Therefore
stoichiometric amounts must be delivered into either the
cytosol of cells [e.g. to block translation (16)] or into the
nucleus [e.g. to redirect splicing (17)] compared with the
amountoftarget RNA.Thus,efﬁcientdeliveryisofparamount
importance to observe strong gene expression control effects.
For some years we have studied the trans-activation activity
of the HIV-1 trans-activator protein Tat which interacts with
the HIVtrans-activation responsiveelement(TAR) stem–loop
RNA and other cellular factors to strongly stimulate trans-
criptional elongation from the viral long terminal repeat
(LTR) (18,19). Inhibitors of these RNA–protein interactions
block full-length transcription and resultant HIV-1 gene
expression, and thus are potential candidates for anti-HIV
therapies. Despite much effort to date, no small molecule
inhibitors [reviewed in Refs (20)] have emerged as clinical
candidates.
Several years ago, we showed that 12mer steric block oli-
gonucleotide analogues of a number of types [e.g. 20-O-methyl
(OMe), a mixmer oligonucleotide containing OMe and some
5-methyl C locked nucleic acid (LNA) units, or a PNA oli-
gomer] targeted to the apical part of the TAR stem–loop,
which is highly sequence-conserved (Figure 1), were able
to inhibit sequence-speciﬁcally Tat-dependent in vitro tran-
scription directed by HeLa cell nuclear extract on a DNA
template containing the HIV-1 LTR (21–23). We then showed
that, when delivered by a cationic lipid or surfactant, 12mer
and 16mer OMe/LNA mixmer oligonucleotides could dose-
dependently and sequence-dependently inhibit Tat-dependent
HIV LTR trans-activation from a stably integrated plasmid
system in HeLa cells with a ﬁreﬂy luciferase reporter, but
without effect on a control Renilla luciferase reporter
(22,23). Fluorescein-labelled OMe/LNA oligonucleotides
were found by confocal microscopy to be located in both
cytosolic and nuclear compartments when delivered by a
range of cationic lipid reagents (23).
Recently, we described the chemical synthesis and
puriﬁcation of disulﬁde conjugates of a range of CPPs with
ﬂuorescein-labelled OMe/LNA oligonucleotides and reported
that in all cases such conjugates were unable to inhibit
Tat-dependent trans-activation in our HeLa cell reporter
assay involving stably integrated reporter plasmids (15).
Whereas in most cases attachment of a CPP signiﬁcantly
enhanced unassisted HeLa cell uptake of the oligonucleotides,
their uptake was conﬁned to cytosolic (presumably
endosomal) compartments. Exclusion from the cell nucleus
correlated with the lack of inhibition of Tat-dependent
trans-activation, suggesting that the barrier to nuclear activity
is due to insufﬁcient release from endosomal compartments.
Similar cytosolic entrapment was also a feature of OMe/
LNA oligonucleotide lipid-free uptake studies into human
ﬁbroblasts (15).
Kaushik et al. (24) found that 15mer and 16mer steric block
PNAs targeted to the TAR RNA, when electroporated into
CEM lymphocytes, were able to inhibit Tat-dependent
trans-activation in a transient luciferase reporter assay and
also block expression of luciferase from CEM cells pre-
infected with pseudotyped HIV-1 virions. 16mer PNA disulf-
ide conjugated to the CPP Transportan [a synthetic chimeric
peptide derived from the neuropeptide galanin and wasp
venom toxin mastoparan (25)] inhibited Tat-dependent
trans-activation in Jurkat or CEM cells or Jurkat cells transi-
ently transfected with luciferase reporters (IC50 of  0.5 mM),
and also inhibited HIV-1 production in chronically infected
H9 cells (IC50 of  1 mM), where it appeared to be acting by
inhibition at the transcriptional level (26). Subsequently,
Chaubey et al. (27) have shown improved activity levels of
the same PNA-Transportan conjugate in an antiviral assay in
blocking synthesis of proviral DNA and signiﬁcantly higher
level of activity (IC50 of  40 nM) by inhibition of viral
infectivity by pre-treatment of HIV virions.
Our current studies address the important question of how
the chemical structure of a CPP–PNA (the type of CPP, its
placement and the type of linkage) relates to its ability to
penetrate HeLa cells, enter the nucleus and inhibit Tat-
dependent trans-activation, which is one of the proposed
mechanisms for attaining antiviral activity. We now report
the chemical synthesis of a range of CPPs conjugated
either through a stable polyether or through a cleavable
disulﬁde linkage to a 16mer PNA targeted to the HIV-1
TAR apical loop. We study their ability to inhibit Tat-
dependent trans-activation when incubated with HeLa cells
using a rigorous, double-luciferase reporter system that
involves stably integrated plasmids. We show that disulﬁde-
linked CPP–PNA conjugates with two types of CPP (Trans-
portan or a novel chimeric peptide R6-Penetratin) are able to
inhibit Tat-dependent trans-activation when incubated with
HeLa cells for 24 h. Co-administration of the lysosomotropic
reagent chloroquine allowed activity to be seen within 6 h.
In addition, trans-activation inhibition could be attained for
several FAM-labelled, stably-linked CPP–PNA conjugates,
notably Tat-PNA, in the presence of chloroquine, which
were inactive in its absence. Confocal microscopy showed
that such CPP–PNA conjugates, when incubated with Hela
cells in the absence of chloroquine, were sequestered in endo-
somal or membrane-bound compartments of HeLa cells,
which varied in appearance depending on the CPP type. In
some cases, co-administration of chloroquine was seen to
release ﬂuorescence from such compartments into the nucleus,
but with different patterns depending on the CPP. The results
are signiﬁcant in that CPP–PNA conjugates of different types
can inhibit Tat-dependent trans-activation in cells and that
endosome or membrane release is a major factor limiting
nuclear delivery and trans-activation inhibition. The results
contribute towards improved design of biologically active
CPP–PNA.
MATERIALS AND METHODS
Assembly of FAM–PNA–peptide conjugates
with stable linkages
These were synthesized manually on a 5 mmol scale using
a polyethylene syringe ﬁtted with a 10 mm polyethyelene
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ﬁltration device, and Fmoc chemistry (28). Fmoc-PAL-PEG-
PS resin and Fmoc (Bhoc) PNA monomers were purchased
from Applied Biosystems and used at 0.2 M dissolved in
N-methylpyrollidone (NMP). The activator was 0.2 M
PyAOP (or PyBOP) in DMF, and a mixture of DIPEA and
2,6-lutidine to give a 0.4 M solution in DMF was used as the
base solution (reagent mix A). For conjugates 1–4 (Figure 2),
after PNA assembly an Fmoc-AEEA spacer (O-linker,
Applied Biosystems) was coupled followed by amino acid
couplings, each carried out with 0.2 M PyBOP in DMF and
0.4M DIPEA (660 ml in 10 ml) in DMF (reagent mix B). For
conjugates 5 and 6, peptide synthesis was carried out before
PNA synthesis and for conjugates 7 and 8, peptide assembly
was both before and after PNA assembly with spacers between
each. Both PNA monomers and amino acid monomers were
double coupled for 30 min per coupling. The resin was washed
ﬁve times with DMF after each coupling. Fmoc deprotection
was carried out with 20% piperidine in DMF (3 min, then
12 min) and resin washed again ﬁve times with DMF.
6-Carboxyﬂuorescein diacetate (6-CDFA; Sigma) (four equi-
valents relative to resin loading) was dissolved in a minimal
volume of NMP and four equivalents of PyBOP dissolved
in DMF added followed by four equivalents of DIPEA. The
mixture was left for 10 min and another 4 equivalents of
DIPEA added to the resin. After 16 h, the resin was washed
thoroughly with DMFand deacetylated by treatment with 20%
piperidine in DMF.
Assembly of (K)8–PNA–K(FAM) (conjugate 9) and
Cys(Npys)–PNA (towards conjugates 10–15)
These were synthesized on 5 mmol scale on an APEX
396 Robotic Peptide Synthesizer using the same reagents
and resin as for manual synthesis. Fmoc deprotection was
carried out with 20% piperidine in DMF (1 min, then 4 min),
amino acid deprotection with 20% piperidine in DMF (3 min
then 12 min). After ﬁve times washing with DMF, PNA was
double coupled using reagent mix A and amino acids were
double coupled using reagent mix B, each with a reaction
time of 30 min per coupling. Boc-Cys(NPys) was used in
the synthesis of PNAs required for disulﬁde coupling.
Fmoc-Lys(Boc) was used for the (Lys)8 sequence and
Fmoc-Lys(Mmt) for the residue for ﬂuorescent labelling.
After washingﬁve timeswithDMF, acapping step wascarried
out using 5% acetic anhydride, 6% 2,6-lutidine in DMF
(2 · 5 min), followed by washing ﬁve times with DMF.
The N-terminal Fmoc group needs to be removed (as above)
before ﬁnal cleavage.
In the case of (Lys)8–PNA–Lys(Mmt), the resin was washed
with DCM and the Mmt group removed by treatment with nine
aliquots of 2% triﬂuoroacetic acid, 5% triisopropylsilane (TIS)
in DCM (5 min incubation for every aliquot, 45 min in total).
The resin was washed with 1·DCM and 1·DMF. To 6-CFDA
(10 equivalents relative to resin loading) dissolved in a min-
imal volume of NMP was added HOAt (10 equivalents)
dissolved in DMF and diisopropylcarbodiimide (DIC)
(10 equivalents), premixed for 10 min, and reacted with the
resin for at least 16 h at room temperature, the resin washed
thoroughly and then deacetylated by treatment with 20%
piperidine in DMF (as above).
Deprotection and purification of PNA
The resin was treated with 95% TFA, 2.5% H2O, 2.5% TIS
with addition of 10% phenol as scavenger for a minimum of
90 min. PNAs were analysed and puriﬁed by reversed phase
high-performance liquid chromatography (HPLC) on a
Phenomenex Jupiter C18 column (see below) with buffer
A, 0.1% TFA in water; buffer B, 10% buffer A in acetonitrile
and monitoring at 260 nm with a gradient of 10–50% B gra-
dient over 30 min. MALDI-TOF mass spectrometry was
carried out on a Voyager DE Pro BioSpectrometry worksta-
tion with a matrix of a-cyano-4-hydroxycinnamic acid,
10 mgml
 1 in acetonitrile-3% aqueous TFA (1:1, v/v). The
accuracy of the mass measurement is regarded as ±0.05%.
Synthesis of Cys peptides
Tat-Cys, R9F2-Cys, Penetratin-Cys and R6-Penetratin-Cys
were purchased as C-terminal amides from Southampton
Polypeptides. Transportan-Cys peptides were synthesized
on a PerSeptive Biosystems Pioneer peptide synthesiser
(100 mmol scale) using standard Fmoc/tert-butyl solid phase
synthesis techniques as C-terminal amide peptides using
NovaSyn TGR resin (Novabiochem). Deprotection of all
peptides and cleavage from solid support was achieved by
treatment with TFA in the presence of triethylsilane and
water (each 3%). Puriﬁcation was carried out by reversed
phase HPLC as described previously (15) and MALDI-TOF
mass spectrometry with the same matrix as for PNA.
Disulfide conjugates of Cys(NPys)–PNA with
Cys-peptides (conjugates 10–15)
To an eppendorf tube containing the Npys-activated PNA
oligomer (20 nmol in 25 ml water) was added 1 M NH4Ac
(pH 7, 10 ml) followed by the Cys-peptide to be conjugated
(40 nmol, 4 ml of 10 mM stock solution). In the case of
Transportan and derivatives, 50 ml of acetonitrile was added
prior to peptide addition to prevent precipitation of the peptide
at neutral pH. The solution was thoroughly mixed and allowed
to stand for 30 min, whereupon the conjugate was puriﬁed in
one aliquot by reversed phase HPLC using a Phenomenex
Jupiter C18 column (5 mm, 300 s, 250 · 4.6 mm
2) heated
to 45 C: Flow rate 1.5 ml min
 1, Buffer A—0.1% TFA
(aqueous), Buffer B—90% acetonitrile, 10% Buffer A. Gra-
dient 5–30% B buffer in 25 min for Penetratin, R9F2, and
R6-Penetratin conjugates (11, 12 and 13, respectively). A gra-
dient of 5–50% B buffer was used for Transportan conjugates
14 and 15. For conjugate 10, a step gradient was necessary
because of close elution of conjugate, Tat and PNA: 5–10% B
(2 min); 10–12.5% B (2 min); 12.5% B (4 min); 12.5–15% B
(2min);15%B(4min);15–17.5%B(2min);17.5%B(4min);
17.5–20% B (2 min); 20% B (4 min). The product was col-
lected, lyophilized and analysed by MALDI-TOF mass spec-
trometry as described above for PNA alone. As an example,
theHPLCpuriﬁcationproﬁlefortheR6–PenC–PNAconjugate
13 (Supplementary Figure 1A), the HPLC analytical proﬁle of
the puriﬁed product (Supplementary Figure 1B) and mass
spectrum (Supplementary Figure 2) are shown.
Inhibition of Tat-dependent trans-activation in cells
Inhibition of HIV-1 Tat-mediated trans-activation by CPP–
PNA conjugates in HeLa cells (Figure 3) was carried out
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experiment two identical 96-well plates were prepared with
10 · 10
3 HeLa Tet-Off/Tat/luc-f/luc-R cells per well and
incubated at 37 C for 24 h. One of the plates was used for
the luciferase assay and the other for the cytotoxicity assay.
Conjugates were prepared at 2.5 mM concentration in Opti-
MEM (Invitrogen), subsequently diluted and added to the cells
for 6 or 24 h incubation, cells washed in phosphate-buffered
saline (PBS) and followed by 18 h incubation in DMEM/10%
fetal bovine serum (FBS). For chloroquine experiments
(Figure 4), conjugates were prepared at 2.5 mM concentration
and 100 mM chloroquine in Opti-MEM, subsequently diluted
by 100 mM chloroquine in Opti-MEM and added to the cells
for 6 h incubation, cells washed as before, followed by 18 h
incubation in DMEM/10% FBS. For the time course study
(Figure 5), incubations with conjugates and 100 mM chloro-
quine were carried out for 2, 4, 6 and 8 h, respectively, before
treatment as above.
Luciferase assay. Cell lysates were prepared and analysed
using the Dual Luciferase Reporter Assay System (Promega)
and relative light units for both ﬁreﬂy and Renilla luciferase
read sequentially using a Berthold Detection Systems Orion
Microplate luminometer. Each data point was averaged over
two replicates of three separate experiments.
Toxicity assay. The extent of toxicity was determined by
measurement of the proportion of live cells colorimetrically
using CellTiter 96 AQueous One Solution Assay (Promega).
The absorbance at 490 nm was read usinga Molecular Devices
Emax Microplate Reader.
Each data point was averaged over two replicates of three
separate experiments. The relative light units in the luciferase
assays were normalized to the absorbance data from the tox-
icity assay, which reﬂects the amount of live cells and then
expressed as a percentage compared with the luciferase activ-
ities of HeLa cells treated in the absence of CPP–PNA. The
error bars reﬂect the full range of the experimental values and
are not SDs. It is common to normalize the ﬁreﬂy luciferase
levels to that of the Renilla luciferase levels when co-
transfection of plasmids is used. However in this stably integ-
rated system, the level of Renilla luciferase is 20-fold lower
than thatofﬁreﬂyluciferase andisthusmuchmoresensitive to
ﬂuctuations resulting from small changes in cell growth con-
ditions. Showing a simple ratio of the two levels unreasonably
ampliﬁes these ﬂuctuations. We have therefore found it more
beneﬁcial to show the two sets of luciferase data separately
(Figures 3 and 4) and to assess the extent of level changes or
otherwise in each set.
Confocal microscopy
HeLa cells (15 · 10
3) were plated on an 8-well Lab-Tek
chambered coverglass (Fisher Scientiﬁc) in DMEM/
10%FBS and cultured overnight. The medium was discarded
and cells were washed with PBS followed by incubation with
300 ml of 2.5 mM CPP–PNA conjugate or 2.5 mM CPP–PNA
conjugate/100 mM chloroquine in OptiMEM for 5.5 h. For
nuclear staining, 50 ml OptiMEM containing hydroethidine
(50 mgm l
 1) was added to each well and incubated for
0.5 h at 37 C. After two washes, 200 ml of OptiMEM (without
phenol red) (Invitrogen) medium containing HEPES buffer
was added into the wells for observation of living cells.
The cells were observed with a Radiance 2100 confocal
system on a Nikon Eclipse TE300 inverted microscope
using a 60· Planapo objective N.A. 1.4.A 488 nm Argon
laserline was used to excite ﬂuorescein and a HQ 515/30
emission ﬁlter was used for observation of the green emission.
Hydroethidine was excited with a 543 nm (green) HeNe laser
and detected using a HQ 570LP (orange) emission ﬁlter.
A dual ﬂuorescence method was used with a differential inter-
ference contrast transmission channel. The images in the three
channels were acquired sequentially at  1 frame/s with a
scanning resolution of 512 · 512 pixels and a Kalman average
of 10 frames was used. When comparing the uptake or activity
of the PNA conjugates the imaging conditions (such as pho-
tomultiplier gain/offset, laser intensities and confocal aperture
size) were kept constant for the observation of the different
conjugates, so that the intensities represent the true differences
in uptake/activity.
RESULTS
In our earlier work, we reported that a 12mer PNA targeted
to residues 24–35 of the apical loop of the HIV-1 TAR
(Figure 1A) blocked Tat binding in vitro as well as Tat-
dependent in vitro transcription in HeLa cell extract (21).
More recently we have studied Tat-dependent trans-activation
activity in HeLa cells and showed that a 16mer OMe/LNA
steric block oligonucleotide was  2-fold more inhibitory than
a12mer(22,23).SinceKaushiketal.(24)showedthata16mer
PNA targeted to TAR (residues 20–34) had several fold larger
inhibitory activity than a 12mer PNA in reverse transcription,
Tat-dependent trans-activation and HIV production assays,
we have focussed ourCPP–PNAconjugatestudies ona similar
16mer PNA targeted to HIV-1 TAR (residues 21–35)
(Figure 1A).
Our HeLa cell line carrying stably integrated luciferase
reporters, used by us in several previous studies (22,23,29),
has signiﬁcant advantages for the study of the inhibition of
Tat-dependent trans-activation activity (Figure 1B). In this
3-plasmid system, HIV-1 Tat is produced in trans to control
production of GL3-ﬁreﬂy luciferase from the HIV-1 LTR,
whilst a control Renilla luciferase is under constitutive
CMV promoter direction. In contrast to the transient plasmid
reporter system of Kaushik et al. (24), in order to see signi-
ﬁcant steric block inhibition of the TAR RNA system, oligo-
nucleotides or PNA must be delivered efﬁciently to the
nucleus of almost all cells, since each cell contains the
three plasmids. The integrated plasmid system would be
expected to mimic more closely an integrated HIV-1 provirus
than transient transfection. Since unconjugated PNA is not
taken up by cells, conjugation with a CPP, minimally a few
Lys residues (17), is essential to achieve at least some cell
binding and entry. We wished to determine how the nature of
the CPP and the way it is linked to the PNA inﬂuences the
ability of the PNA component to enter the cell, reach the
nucleus and inhibit Tat-dependent trans-activation.
Synthesis of stably-linked and disulfide-linked
conjugates of CPPs to 16mer PNA
A series of stably-linked CPP–PNA conjugates was synthes-
ized using the Fmoc method (28), where the linkage between
6840 Nucleic Acids Research, 2005, Vol. 33, No. 21the PNA and peptide parts consisted of a short polyether link-
age (AEEA, 8-amino-3,5-dioxo-octanoic acid, also known as
an O-linker) (Figure 2A, conjugates 1–8). All conjugates were
puriﬁed by reversed phase HPLC and characterized by
MALDI-TOF mass spectrometry. CPPs used were either the
Tat peptide (residues 48–58) (30), an SV40 nuclear localiza-
tion signal (NLS) (31,32), Transportan (25) or a shorter 21mer
version of Transportan [known as TP10 or Transportan 21
(33)]. In conjugates 1–4, a single CPP (Tat, Transportan,
TP10 or NLS, respectively) was linked to the N-terminus of
the 16mer PNA, spaced by an O-linker (Figure 2A). In con-
jugates 5 and 6, a single CPP (TP10 or NLS) was linked to the
C-terminus of the PNA, spaced by an O-linker. In conjugates
7 and 8, both NLS and Tat CPPs were added, one on each end
in different order, each spaced by an O-linker. A carboxyﬂuor-
escein (FAM) label was coupled to the N-terminus of each
conjugate to enable cell ﬂuorescence uptake studies.
A different type of stably-linked CPP–16mer PNA conjug-
ate was also synthesized that carried eight lysine residues on
the N-terminus [Figure 2A, conjugate 9]. Conjugate 9 was
prompted by the work of Siwkowski et al. (34) who showed
that a K8–PNA construct was very effective at redirection of
splicing of a CD40 mRNA when added to BCL1 or macro-
phage cells, and that this was due to enhanced cell uptake
resultant from the use of the K8 conjugate acting effectively
as a CPP. In conjugate 9, the FAM label was attached to the
PNA moiety on the C-terminus via the e-amino group of a
single K residue.
In order to compare with the Transportan-PNA conjugate of
Kaushik et al., (26) which utilized a disulﬁde linkage, we
synthesized a range of CPP–PNA conjugates that contained
a disulﬁde linkage (Figure 2B). These were synthesized by
conjugation of Cys–peptides with Cys–PNA activated with a
nitropyridylsulfenyl (NPys) group, puriﬁed by reversed phase
HPLC and characterized by MALDI-TOF mass spectrometry.
Six such conjugates were prepared (Figure 2B) from PNA
16mer containing three C-terminal K residues and as CPPs
either Tat (30), Penetratin (35), R9F2 (36), Transportan or a
novel R6-Penetratin chimeric peptide that we have described
recently (15). In four cases (10–13) the Cys residue was
located on the C-terminus of the peptide, in one case Trans-
portan was placed at the N-terminus (14) [which is similar
to that described previously by Kaushik et al. (26)], and
in the case of construct 15, a Cys residue replaced K-13 in
Transportan.
Inhibition of Tat-dependent trans-activation
by CPP–PNA
We tested the ability of CPP–PNA constructs to inhibit Tat-
dependent trans-activation by incubation with HeLa Tet-Off/
Tat/luc-f/luc-R cells (21,23) for 6 or 24 h in the absence of any
transfection agent. Cells were then washed and subsequently
grown for 18 h. Fireﬂy luciferase activity results from HIV-1
Tat-dependent transcription, whilst Renilla luciferase activity
acts as an internal control to check that there is no inhibition of
general transcription/translation.
In the case of stably-linked conjugates 1–9, there was no
signiﬁcant reduction seen either of ﬁreﬂy luciferase or Renilla
luciferase expression up to 2.5 mM tested (data not shown).
We then tested the six disulﬁde-linked CPP–PNA conjugates.
Tat, Penetratin and R9F2 conjugates 10–12 showed no activity
up to 2.5 mM tested (data not shown). For 6 h incubation
(Figure3A,upper panel),theR6-Penetratin disulﬁde conjugate
13 showed no activity, but both Transportan disulﬁde conjug-
ates 14 and 15 showed a small dose-dependent reduction of
ﬁreﬂy luciferase activity(Figure 3A, upper panel). The Renilla
luciferase activity did not drop signiﬁcantly over the same
concentration range (Figure 3A, lower panel). Note that the
absolute level of Renilla luciferase activity in terms of light
units is only 5–10% of that of the ﬁreﬂy luciferase in this
cell line. Sporadic increases in Renilla luciferase ﬂuorescence
for particular constructs are occasionally observed, e.g. con-
struct 14, reﬂecting the much higher sensitivity of the Renilla
luciferase to additives or cell growth conditions compared
with ﬁreﬂy luciferase. A signiﬁcant reduction in Renilla luci-
ferase expression would have been expected had there been
any non-speciﬁc transcription/translation suppressive effect
upon addition of the CPP–PNA, which is clearly not the case.
Cell viability for 6 h incubation with the highest concentration
A
B
Figure1.(A)SecondarystructureoftheTARRNAapicalstem–loop,thebindingsiteonTARandsequenceofthePNA16mer.(B)Stablyintegratedplasmidswithin
the HeLa Tet-Off/Tat/luc-f/luc-R cell line used for trans-activation inhibition studies.
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and for disulﬁde-linked conjugates was >90%.
For 24 h delivery of the CPP–PNAs, a strong dose-
dependent reduction of ﬁreﬂy luciferase activity was
seen for all three conjugates 13–15 (Figure 3B, upper
panel), whilst no signiﬁcant reduction in Renilla luciferase
activity was seen in any case (Figure 3B, lower panel, note
that in this case there was no signiﬁcant sporadic increase for
the same conjugate 14). Thus the R6-Penetratin and the
two Transportan conjugates of PNA 16mer, in contrast to
Tat, Penetratin and R9F2 conjugates, must in some way assist
signiﬁcant amounts of PNA to reach the nucleus and interact
with TAR RNA during the extended time 24 h time period
in order to show such strong inhibition of Tat-dependent
trans-activation.
Effect of chloroquine addition on CPP–PNA conjugates
In common with most types of biomolecules, it is well known
that oligonucleotides and their analogues enter most cells via
an endocytotic pathway,ofwhich thereare many types (37).In
our previous studies with CPP conjugates of LNA/OMe
oligonucleotides, confocal microscopy evidence was obtained
that the most probable limiting factor in obtaining trans-
activation inhibition was sequestration within endosomal
or other membrane-bound cytosolic compartments (15). We
Figure 2. (A) Structures of various FAM-labelled stably-linked CPP–PNA and PNA–CPP conjugates 1–9 and their calculated and observed mass values.
(B) Structure of various disulfide-linked CPP–PNA conjugates 10–15 and their calculated and observed mass values. The linkage is in all cases between an
N-terminal Cys residue on the PNA and a Cys residue within the peptide either on the C-terminus (10–13) N-terminus (14) or an internal residue (15). These
conjugates do not carry a FAM label.
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could enhance the release of CPP–PNA conjugates from such
compartments. Chloroquine is an anti-malarial drug and a
weak base that passes through membranes in its unprotonated
form and accumulates in acidic compartments, such as lyso-
somes and endosomes, where it leads to osmotic swelling (38).
The reagent has been used to study endosomal uptake of
antisense oligodeoxynucleotides (1,39,40). The reagent is
thought to promote the disruption of endosomal compart-
ments. Similarly lysosomotropic agents increase the efﬁciency
of transgene expression by non-viral delivery vectors (41,42).
We therefore carried out the trans-activation inhibition
assay with the HeLa cell reporter system with addition of
CPP–PNA for 6 h in the presence of 100 mM chloroquine,
cells washed and grown for a further 18 h. For stably-linked
Tat-PNA conjugate (1), there was now seen a signiﬁcant
level of reduction of ﬁreﬂy luciferase (Figure 4A). A smaller
reduction (reduction most noticeable at the highest CPP–PNA
concentration used) was seen for Transportan-PNA (2),
TP10–PNA (3), NLS–PNA–Tat (7) (Figure 4A) and also
for PNA–TP10 (5) and Tat–PNA–NLS (8) (data not shown).
No inhibitory activity was observed for NLS–PNA (4)o r
PNA–NLS (6) or for K8–PNA (9) (data not shown). No reduc-
tion was seen of Renilla luciferase activity in any case (data
not shown). Cell viability was >85% for all stably-linked
CPP–PNAs in the presence of chloroquine.
The three CPP–PNA disulﬁde conjugates (13–15) that had
previously shown high ﬁreﬂy luciferase inhibition activity at
24hintheabsenceofchloroquine(Figure3B)showedastrong
dose-dependent inhibition of ﬁreﬂy luciferase expression
when chloroquine was co-administered with the CPP–PNA
for 6 h (Figure 4B). No reduction was seen in any case in
Renilla luciferase expression as conjugate concentration was
increased (data not shown). A small increase in Renilla
luciferase activity was again seen at high CPP–PNA concen-
tration in occasional cases (data not shown). Cell viability was
>70% for the disulﬁde-linked conjugates in the presence of
chloroquine.
To show that sequence-speciﬁcity is maintained when
chloroquine is co-administered, we tested controls of R6-
Pen-S-S-PNA (13) with scrambled and mismatched PNA
sequences and both of these showed no inhibitory activity
of ﬁreﬂy luciferase expression (Figure 4B). Similar scrambled
and mismatched controls for Transportan disulﬁde PNA con-
jugate 14 were also inactive (data not shown). Thus chloro-
quine addition has no effect on the sequence-speciﬁcity of the
inhibition of Tat-dependent trans-activation of the active
CPP–PNAs. No effect was seen of 100 mM chloroquine on
HeLa cell viability (data not shown) and the level of ﬁreﬂy
luciferase activity was not signiﬁcantly affected by chloro-
quine alone (Figure 4A and B, minus chloroquine control).
However, chloroquine alone treatment did show a reduction
Figure 3. Trans-activationinhibitoryeffectsofdisulfide-linkedCPP–PNAconjugates13–15intheHeLacellreporterassaywith6hdelivery(A)or24h(B).Firefly
luciferase activity represents Tat-TAR dependent expression whilst Renilla luciferase activity represents control constitutive expression. Bars (left to right) in each
case represent 2.5, 1.25, 0.625, 0.312 and 0 mM CPP–PNA concentrations.
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CPP–PNA was added) (data not shown).
Overall the chloroquine co-administration data are con-
sistent with the hypothesis that release from endosomal or
membrane-bound compartments is limiting in attaining
trans-activation inhibition activity for CPP–PNA conjugates.
Since some stably-linked CPP–PNAs gained activity when
chloroquine was co-administered (Figure 4A), a cleavable
disulﬁde bond between CPP and PNA is clearly not essential.
However, there is not as yet a fully consistent structure–
activity relationship, since no signiﬁcant inhibition of ﬁreﬂy
luciferasewasseenwith co-administration ofchloroquinewith
Tat-S-S-PNA, Penetratin–S-S–PNA and R9F2–S-S–PNA
disulﬁde conjugates 10–12 for 6 h (data not shown), which
were also inactive in the absence of chloroquine (data not
shown).
To look at the time course for the effect of chloroquine
on nuclear Tat-dependent trans-activation inhibition activity,
we co-incubated 2.5 mM of the most active stably-linked
conjugate, Tat-PNA (1), with 100 mM chloroquine for dif-
ferent times, washed the cells and continued growth in each
case for 18 h. The results showed that the majority of the
inhibitory effect is seen within 6 h with very little additional
reduction in ﬁreﬂy luciferase activity after 8 h (Figure 5).
Similar time courses were seen for lower concentrations of
Tat-PNA, with correspondingly smaller ﬁreﬂy luciferase
expression reductions (data not shown). This shows that
6 h co-administration, the time point when the set of data
in Figure 4 was taken, was reasonably well chosen to
see most of any observable trans-activation inhibition
enhancement effect.
Confocal microscopy of FAM-labelled CPP–PNA in the
absence and presence of chloroquine
To obtain visual evidence for chloroquine release from endo-
somal or membrane-bound compartments, we examined by
live-cell confocal microscopy the ability of FAM-labelled
constructs to enter the HeLa cells after 5.5 h, a similar time
to that used for the activity experiments (Figure 6). A hydro-
ethidine dye was used to stain the cell nucleus, which makes it
easier to observe any nuclear uptake (green colour or yellow
colour when overlayed), but also only the nuclei of live cells
are stained red, ensuring that only healthy cells are included
Figure 4. Trans-activation inhibitory effects (firefly luciferase activity) of CPP–PNA conjugates in the HeLa cell reporter assay with delivery for 6 h in the
presenceof100 mMchloroquine.(A) Stably-linked conjugates Tat–PNA(1),TP–PNA(2),TP10–PNA(3) andNLS–PNA–Tat(7).(B) Disulfide-linked conjugates
R6–Pen-S-S–PNA (13), mismatched conjugate 13 (PNA sequence, CTCCGCAGCTCAGATC), scrambled conjugate 13 (PNA sequence, ATCGCTCGCAC-
CATGC), TP–S-S–PNA (14) and TP(int)–S-S–PNA (15). Bars (left to right) in each case represent 2.5, 1.25, 0.625, 0.312 and 0 mM (light shaded bar)
CPP–PNA concentrations. Control (black bar), absence of CPP–PNA and absence of chloroquine.
Figure 5. Trans-activation inhibitory effects (firefly luciferase activity) of
2.5 mM Tat-PNA (1) incubated for 2, 4, 6 or 8 h, respectively, with HeLa
reporter cells, cells washed and grown for 18 h before assay.
6844 Nucleic Acids Research, 2005, Vol. 33, No. 21in observations (Figure 6A and C, orange ﬁlter). Figure 6B
and D shows green emission only. Note that all confocal
microscopy experiments used live cells that are unﬁxed and
which are not subject to artefacts of cell ﬁxation (43).
All FAM-labelled CPP–PNA constructs 1–9 showed signi-
ﬁcant cell uptake. For example in the absence of chloroquine,
Tat-PNA (1) showed a punctate distribution of ﬂuorescence in
the cytosol with rather small puncta that were quite well dis-
tributed and typical of endosomal sequestration (Figure 6A
and B, ﬁrst line). In contrast Transportan–PNA conjugate (2)
(Figure 6A and B, second line) and TP10–PNA (3) (data not
shown) showed strong uptake but a quite different distribution,
being concentrated either at or close to the cell surface in large
aggregates, with just a few large puncta seen within the cyto-
sol. FAM-labelled constructs containing both NLS and Tat
peptides showed a punctate distribution more akin to that
of Tat–PNA. For example NLS–PNA–Tat (conjugate 7,
Figure 6A and B, third line) showed both small and large
cytosolic puncta. The K8-PNA uptake pattern (conjugate 9)
(Figure 6A and B, fourth line) looked very similar to that
of Tat–PNA conjugate 1. Since the FAM label in the case of
K8–PNA is on the C-terminus of the PNA (compared with the
N-terminus of the peptide in the case of Tat–PNA), this gives
conﬁdence that any ﬂuorescence seen is due to intact CPP–
PNAs during the 5.5 h delivery period and not as a result of
FAM label release. The lack of signiﬁcant nuclear ﬂuores-
cence seen in all four conjugate cases is consistent with
the lack of activity of the stably-linked CPP conjugate con-
structsin the trans-activationinhibition assay in the absenceof
chloroquine.
Confocal microscopy of HeLa cells treated for 5.5 h with
FAM-labelled Tat–PNA in the presence of 100 mM chloro-
quine was informative. Conjugate 1 (Figure 6C and D, ﬁrst
line) showed in addition to punctate structures in the cytosol,
Figure 6. Confocalmicroscopyimagesoftheuptakeoffluorescein(FAM)-labelledCPP–PNAconjugateswhenincubatedfor5.5hwithunfixedHeLacells.Nuclei
are stained red with hydroethidine. (A and C) Orange filter to view both the red colour of hydroethidine and the fluorescein fluorescence. (B and D) Green filter to
view only the fluorescein fluorescence. (A and B) Show incubations in the absence of chloroquine, (C and D) Show incubations in the presence of 100 mM
chloroquine. First line Tat–PNA (1); second line Transportan–PNA (2); third line NLS–PNA–Tat (7); fourth line K8–PNA (9). In (C), second line, yellow dots are
marked with arrows showing co-localization of hydroethidine dye and fluorescein fluorescence on the inner wall of the nucleus in several nuclei.
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leus. This is particularly apparent in the image taken with
green emission (Figure 6D), where the hydroethidine red col-
our is not visible. In contrast, Transportan–PNA (conjugate 2)
in the presence of chloroquine showed the majority of the
ﬂuorescence as large aggregates at or close to the cell surface
(Figure 6C and D, second line), similar to that seen in the
absence of chloroquine (Figure 6A and B). However with
hydroethidine staining (Figure 6C) some of the nuclei showed
yellow spots (owing to overlay of red and green) just inside the
nuclearmembrane(yellowarrows).Therewasvery littlegreen
ﬂuorescence seen in the cytosol under the green emission
(Figure 6D). This suggests that the Transportan–PNA conjug-
ate2mayhave quitedifferentcharacteristicsofcelluptakeand
trafﬁcking.
NLS–PNA–Tat (7) (Figure 6C and D) showed general ﬂuor-
escence release very similar to that of Tat–PNA (1), but less
strongly. The same result was seen for Tat–PNA–NLS (8)
(data not shown). Other constructs such as K8–PNA (9)
(Figure 6C and D) did not show strong evidence of uniform
cell ﬂuorescence when chloroquine was co-administered and
the ﬂuorescence remained punctate, similar to that in the
absence of chloroquine (Figure 6A and B). The overall ﬂuor-
escence in the cytosol (either in endosomes or general)
appeared to be higher in many cases when chloroquine was
used,butoneshouldnotethattheoveralllevelsofﬂuorescence
cannot be directly compared in the presence and absence of
chloroquine, because ﬂuorescein has substantially reduced
ﬂuorescence at the low pH value found within endosomes
and chloroquine itself (being a base) is also likely to affect pH.
Overall, the confocal microscopy results show that the
nature of the CPP attached stably to the PNA by O-linker
affected both the type of vesicular structure seen in the cytosol
(mostly punctate or mostly aggregates at the cell surface) as
well as whether and how the ﬂuorescence is released by chlor-
oquine addition. It is clear that basic peptides such as Tat
promote a radically different cell uptake pattern of PNA (con-
jugate 1) from that of Transportan (conjugate 2). In general,
confocal microscopy data provides additional evidence for
sequestration of CPP–PNA in endosomal or membrane-
bound compartments.
DISCUSSION
The importance of this study centres on how the type of CPP
and the way it is linked to a PNA 16mer directed against a
HIV-1 TAR target affects the ability of PNA to inhibit Tat-
dependent trans-activationinHeLa cellnuclei usingourstably
integrated, double-luciferase reporter plasmid system. The
TAR apical stem–loop is a well-validated, steric block anti-
sense target by us (15,22,23,29) and by others (24,44,45).
Dose-dependence and sequence-speciﬁcity in cells was estab-
lished previously using lipid-delivered oligonucleotide ana-
logues. Inhibition at the RNA level was veriﬁed using a
Tat-dependent transcription assay with HeLa cell nuclear
extract (22,23). In the current study, we found that two
disulﬁde-linked conjugates of 16mer anti-TAR PNA to Trans-
portan (linked in different ways) or a novel R6-Penetratin
chimeric peptide (conjugates 13–15) were able to inhibit intra-
cellular trans-activation at a signiﬁcant level when incubated
for 24 h (Figure 3). In contrast, PNA conjugates disulﬁde-
linked to Tat, Penetratin and R9F2 (10–12) and a range of
CPP conjugates having stable O-linkers between CPP and
PNA components (1–9) were unable to elicit trans-activation
inhibition (data not shown).
We have used co-administration of the lysosomotropic
reagent chloroquine to provide strong evidence that the barrier
to high trans-activation inhibition activity in the nucleus is
poor release from endosomes or other membrane-bound com-
partments. The three disulﬁde-linked CPP–PNA conjugates
13–15 that showed inhibition on their own when incubated
with cells for 24 h also showed substantial activity within 6 h
in the presence of chloroquine, and the sequence-speciﬁcity of
the inhibitory activity was maintained (Figure 4B). Some
stably-linked conjugates that were inactive when delivered
alone, e.g. Tat–PNA conjugate 1, were able to gain signiﬁcant
inhibitory activity in the presence of chloroquine (Figure 4A).
The time course of the trans-activation inhibitory activity
showed that most of the effect occurred within 6 h
(Figure 5). Thus an unstable disulﬁde linkage is not a pre-
requisite for activity if endosomal release can be enhanced by
chloroquine. Surprisingly, activity was not enhanced signiﬁc-
antly for some other conjugates, notably PNA disulﬁde-linked
to Tat, Penetratin and R9F2 (conjugates 10–12, data not
shown). This shows that the structure–function relationship
of inhibition activityand chloroquine enhancement is complex
and notjusta matter ofcleavableversusstable linkage.Clearly
though, disulﬁde-linked CPP–PNA 13–15 were the only ones
that worked in the absence of chloroquine.
Folini et al. (46) described recently a photochemical
approach to trigger endosomal release from adenocarcinoma
cells DU145 of a naked PNA targeted to hTERT mRNA.
Incubation of 18 h with high PNA concentration (10 mM)
and a photosensitizer was used followed by a 60–80 s ﬂuor-
escent light treatment. A signiﬁcant reduction in telomerase
activity was observed in cell extracts and some microscopy
evidence was obtained for ﬂuorescent PNA redistribution into
cytosol and nucleus from endosomal vesicles. A stably-linked
Tat–PNA was only slightly active at 2 mM when incubated for
48 h but these authors did not test photochemical release of
Tat–PNA (46). Whilst consistent with Folini et al. (46), our
data is important in that we have used CPP–PNAs, which have
much better cell uptake and therefore can be used at lower
concentration, short delivery periods (6 h) and a deﬁnite nuc-
lear target (hTERT mRNA could have been inhibited either
in cytosol or nucleus), as well as a known drug, chloroquine,
to demonstrate endosomal release is limiting in attaining
trans-activation inhibition in HeLa cells.
We observed endosomal and/or membrane sequestration for
several stably-linked FAM-labelled CPP–PNA tested
(Figure 6). This is consistent with previous observations by
others in several cell lines for ﬂuorescently labelled Tat–PNA
and Penetratin–PNA, whereas no uptake was observed for
PNA alone (4). The very different confocal microscopy uptake
patterns of Tat–PNA (1) and Transportan–PNA (2) conﬁrm
previous suggestions that there are at least two classes of CPP,
one broadly encompassed by Arg-rich domains, such as Tat
(47) and our novel chimeric peptide R6-Penetratin (15), and
another by the more hydrophobic peptide Transportan
(25,26,48). We found clear evidence for conjugate release
from endosomes by confocal microscopy in the cases of
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(7) (Figure 6). There was also some evidence of release into
the nucleus for stably-linked Transportan–PNA (2). In this
case there was no general cytosolic ﬂuorescence but instead
a different localization pattern that suggests an alternative
trafﬁcking pathway for Transportan–PNA.
Our experiments here do not address directly the issue of the
type of uptake pathway(s) for the two types of CPP–PNA
conjugate nor the precise role of chloroquine in facilitating
activityandnucleardelivery.Thepunctateendosomallocation
of Tat–PNA 1, the ﬂuorescence release (Figure 6) and the gain
of trans-activation inhibition activity (Figure 4) are all com-
pletely consistent with our previous data on Tat peptide and
Tat–PNA showing sequestrationinacidic endosomal compart-
ments (43). In contrast, Transportan clearly directs the PNA
into membrane-bound vesicular compartments that are differ-
enttothoseofTat–PNA conjugates(compare conjugates 1and
2 in Figure 6). Recently published studies with several cell
lines using FACS analysis concluded that a TAMRA-labelled
disulﬁde-linked Transportan–PNA was not taken up by a
receptor-mediated or endocytotic process because the kinetics
of uptake were not affected by low temperature or by the
addition of phenylarsine oxide (27). Our results on chloro-
quine enhancement of trans-activation activity of two types
of disulﬁde-linked TP–PNAs (13 and 14, Figure 4B) suggest
thatsomesort ofendosomalrouting may neverthelessoccur,at
least in part. However, the clearly different pattern of uptake
seen for stably-linked TP–PNA (2) in the absence and pres-
ence of chloroquine to that of Tat–PNA (1) and other cationic
peptides (Figure 6) implies that a non-endocytic pathway of
delivery is possible in the case of TP–PNA. Further compar-
ative data between the two types of conjugate using speciﬁc
classes of endocytosis inhibitor, as well as other cell trafﬁck-
ing analysis techniques, will be required to address this point
with sufﬁcient clarity.
We found that minimal CPPs, such as a stably-linked K8–
PNA conjugate 9 which was FAM-labelled at the C-terminus
of the PNA, were not active in our assay up to 2.5 mM tested,
even in the presence of chloroquine (data not shown). Nor did
we see evidence for cytosolic release (Figure 6, fourth line).
The fact that similar punctate ﬂuorescence patterns were
observed in the absence of chloroquine for both N-terminal
FAM-labelled Tat–PNA and C-terminally labelled K8–PNA
(Figure 6, compare ﬁrst and fourth lines) suggests that the
ﬂuorescence observed reﬂects intact CPP–PNA conjugate. It
should be noted that biotin labelled Tat, Penetratin and R9
peptides internalized in cells for several hours and rapidly
isolated from cells without chance of proteolysis during isola-
tion were found to be predominantly intact (49).
In work carried out in parallel using a K8–PNA construct
directed to a splice site to redirect splicing and up-regulate
production of luciferase, chloroquine co-treatment allowed
partial splicing correction and increased luciferase expression
in keeping with partial release of the conjugate entrapped
within endosomal compartments (50). Treatment with sucrose
(which is also believed to promote endocytic vesicles swelling
and destabilization) gave similar data. We believe that the
splicing correction assay is probably much more sensitive
than the anti-TAR trans-activation inhibition assay described
here.WenotethatinadifferentsplicingassayIC50sforsimilar
Kn–PNA conjugates were in the micromolar range (34).
Our work complements well previous studies using a
disulﬁde-linked Transportan–PNA conjugate which was
shown to inhibit HIV-1 production in chronically infected
H9 cells (IC50 of 1 mM) when treated in culture for 6 h
(26). In our Tat-dependent trans-activation assay, two differ-
ent disulﬁde-linked Transportan–PNA conjugates and also an
R6–Penetratin–PNA conjugate showed similar inhibition
levels (IC50 of 0.5–1 mM) (Figure 3) but in each case strong
inhibition was only seen after 24 h delivery. Our evidence
suggests that CPP–PNA conjugates are sequestered in endo-
somal or membrane-bound compartments and thus only
slowly released. For further studies, we are currently con-
structing disulﬁde-linked PNA–peptide conjugates ﬂuores-
cently labelled on the N-terminus of the PNA. Preliminary
confocal microscopy studies on a Tat conjugate showed punct-
ate endosomal sequestration similar to the stably-linked
conjugates 1 and 9 (A.A. Arzumanov, unpublished data).
Our studies are important also in consideration as to what
extent antiviral effects of PNA-peptides might be due to
inhibition of Tat-dependent trans-activation. Chaubey et al.
(27) found recently that their disulﬁde-linked Transportan–
PNA conjugate was active with IC50 of 500 nM in an HIV
infection inhibition assay when HIV-1 was used to infect CEM
cells in the presence of conjugate. Because these experiments
were carried out by co-incubation of virus and conjugate with
cells, antiviral activity could arise for several reasons, such as
interference with viral uptake, inhibition of reverse transcrip-
tion within partially uncoated virions within the cytosol
of infected cells, or by inhibition of Tat-dependent trans-
activation once the proviral DNA has been integrated into
the host. Blocking of reverse transcription in vitro by steric
block oligonucleotides and PNA complementary to TAR has
been well known for some years (51,52) but to what extent
this can occur within cells is currently unclear. Our results
show that blocking Tat-dependent trans-activation is a pos-
sible activity in cells, as evidenced by our robust integrated
plasmid assay, and that this can be effected by two types
of disulﬁde-linked TP–PNA and a new R6–Penetratin–PNA.
However, this cell activity was only obtained strongly after
24 h incubation.
Our results suggest that entrapment within endosomal or
membrane compartments is probable to limit the antiviral
activities of many PNA–peptide conjugates and thus there
would now be great beneﬁt in investigation of a much
wider CPP range that might further enhance endosomal or
membrane release. For example, our disulﬁde-linked R6–
Penetratin–PNA conjugate clearly belongs to a different
class to Transportan–PNA conjugates. This peptide is a chi-
mera between Penetratin and a short poly-Arg sequence (53),
which is thought to act similarly to Tat peptide. This chimera
is therefore a double CPP. We hope to extend our studies
to antiviral activities of this and other similar CPP–PNA
conjugates in the future.
Chaubey et al. (27) also showed that their TP–PNA con-
jugate was much more highly effective as a virucidal agent
with a dose median of 66 nM when HIV-1 virions were pre-
treated with conjugate before infection of cells. This activity
cannot be due therefore to trans-activation inhibition. The
conjugate was shown to cause abortive termination of
reverse transcription within virions, but only when treated
at the much higher dose of 0.5 or 1.0 mM. Thus it is not
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prevent cell attachment or entry. Further, during preparation
of this manuscript, Tripathi et al. (54) reported synthesis of
Transportan, Transportan TP10 and C-terminally truncated
Transportan-linked through a Cys residue added to e-amino
group of Lys-13, as well as Penetratin and Tat peptides linked
through their N-termini, in each case to the N-terminus of
ﬂuorescein-labelled16merPNA.Interestingly,theHIV-1viru-
cidal activities all fell within a narrow range (28–72 nM dose
median) with the Penetratin conjugate being the best, whilst
antiviral activities varied from 400 nM IC50 for full-length
Transportan conjugate to 1.1 mM for truncated Transportan
conjugates. Penetratin and Tat conjugates showed 800 and
720 nM IC50 respectively. There was no clear correlation of
the level of cell uptake as measured by FACS analysis with
antiviral activity, and no cell localization experiments were
reported.
Contrary to the observations of Tripathi et al. (54), who
suggested that all these disulﬁde-linked conjugates are taken
up by cells by similar non-endocytotic pathways, because
uptake was not seen to be inhibited at 4 C, our confocal
microscopy data (Figure 6) suggest sequestration of CPP–
PNA in endosomal or membrane-bound compartments and
release in the presence of the lysosomotropic reagent chlor-
oquine. Clearly our trans-activation inhibition data (Figures 3
and 4) show that two classes of CPP (Transportan and R6–
Penetratin) disulﬁde-linked to PNA enable nuclear activity to
be attained. No clear literature data are available as to whether
intracellular cleavage of their disulﬁde linkages occurs or if
PNA–peptide conjugates are released intact from the endo-
some or other membrane-bound compartment. Confocal
microscopy studies of disulﬁde-linked conjugates carrying
different ﬂuorophores on PNA and peptide parts (32) may
help to address this issue. But our important data show that
a cleavable bond is not essential in principle since stably-
linked Tat–PNA 1 is strongly active when chloroquine is
co-administered (Figure 4B).
Whilst this manuscript was undergoing review, a paper was
published showing that 6 mM calcium ions or 60–120 mM
chloroquine co-administration increased the ability of stably-
linked Tat-O-PNA or R7–PNA to correct mis-splicing of luci-
ferase mRNA 44- and 8-fold, respectively, in the nucleus of
HeLa pLuc 705 cells, but no effect was observed for naked
PNA (55). Evidence was presented that the mechanism
involves endosomal release. The results presented are fully
consistent with our data.
The TAR apical stem–loop target is highly sequence-
conserved and is one of several potential targets in the
HIV-1 RNA leader suitable for development of oligonuc-
leotide antiviral agents. For example, we reported recently
that 16mer OMe/LNA oligonucleotides targeted to TAR,
when delivered by cationic lipids, could inhibit HIV replica-
tioninaHeLa T4 b-galactosidase cellline(56).PNA–peptides
have particularly high potential because of their dual potential
for antiviral and virucidal activities and the lack of need for a
transfection agent. We are now in a position to improve on
such activities by carrying out structure–activity relationships
with further peptide–PNA conjugates, concentrating on
improving their membrane penetration and endosomal release
properties.
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